It is important to assess whether Rap2a gene can be used as biomarkers to predict tumor metastasis and guide the choice of therapy, which is why we investigated the level of Rap2a expression in RCC patients as well as their associations with clinicopatological features. The gene discussed is RAP2A; the disease is neoplasm.